# Regimens Comparison for Breast Cancers of Positive Lymph Nodes

> **NCT01134523** · PHASE3 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 1000 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Epirubicin, CTX, Paclitaxel
- **DRUG:** Epirubicin, Paclitaxel

## Key facts

- **NCT ID:** NCT01134523
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-05
- **Primary completion:** 2018-05
- **Final completion:** 2020-05
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2013-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01134523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01134523, "Regimens Comparison for Breast Cancers of Positive Lymph Nodes". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01134523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*